Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Treatment Approaches and Clinical Outcomes for Relapsed/Refractory Multiple Myeloma in Asia: A Multicenter Asian Myeloma Network Study (AMN010)

  • By

  • Melinda SY Tan

  • Kye Ling Wong

  • Cinnie Soekojo

  • Chandramouli Nagarajan

  • Sarah Burkhill

  • Xinhua Li

  • Ho-Jin Shin

  • Jong Heon Jung

  • Yeung-Chul Mun

  • Ho-Young Yhim

  • Jae Hoon Lee

  • Ling Cao

  • Tadao Ishida

  • Chihiro Shimazaki

  • Makoto Sasaki

  • Hiroyuki Takamatsu

  • Shinsuke Iida

  • Hirono Iriuchishima

  • Shuji Ozaki

  • Karen Tang

  • Jeffrey Huang

  • Jerry Teng

  • Cheng-Shyong Chang

  • Changki Min

  • Wenming Chen

  • Hiroshi Handa

  • Kihyun Kim

  • Priti Bahety

  • Juan Du

  • Wee Joo Chng

  • November 11, 2026

Share

  • 1

    This retrospective study included 1,123 patients with relapsed/refractory multiple myeloma treated across six Asian countries and regions during 2020–2022.

  • 2

    Treatment patterns varied widely, with 75 regimens in second line, 79 in third line, and 52 in fourth line; triplets predominated, while monotherapy was most common in fourth line.

  • 3

    Outcomes worsened with successive treatment lines: median progression-free survival declined from 16.1 months in second line to 9.1 months in third line and 5.2 months in fourth line.

  • 4

    Overall response rates decreased from 71.6% in second line to 58.9% in third line and 43.6% in fourth line.

  • 5

    Greater drug-class refractoriness was associated with poorer outcomes, and triple-class refractory patients had the shortest median progression-free survival across treatment lines.

Original Source(s)

Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)

  • by Melinda SY Tan, Kye Ling Wong, Cinnie Soekojo, Chandramouli Nagarajan, Sarah Burkhill, Xinhua Li, Ho-Jin Shin, Jong Heon Jung, Yeung-Chul Mun, Ho-Young Yhim, Jae Hoon Lee, Ling Cao, Tadao Ishida, Chihiro Shimazaki, Makoto Sasaki, Hiroyuki Takamatsu, Shinsuke Iida, Hirono Iriuchishima, Shuji Ozaki, Karen Tang, Jeffrey Huang, Jerry Teng, Cheng-Shyong Chang, Changki Min, Wenming Chen, Hiroshi Handa, Kihyun Kim, Priti Bahety, Juan Du, Wee Joo Chng

  • November 11, 2026

Related Content

FDA Updates Potency Rules for Cell and Gene Therapies

Replacing guidance from 2011, the FDA's updated framework emphasizes potency assurance throughout cell and gene therapy development and manufacturing

  • November 11, 2026

  • 3 min
Roswell Park is a Center of Excellence for Rectal Cancer Surgery

Roswell Park Comprehensive Cancer Center is a nationally accredited and certified Center of Excellence for colorectal cancer surgery due to the high volume of procedures completed annually for patients with colon and rectal cancer.

  • October 27, 2026

  • 2 min
Engineering a New Generation of Cancer-Fighting Cells

USC researchers develop a scalable cell engineering platform that could overcome key manufacturing and therapeutic limitations of CAR-based immunotherapies

  • October 28, 2026

  • 3 min